Chosen for nearly one out of every two endovascular abdominal aortic aneurysm (AAA) repairs worldwide, the Endurant II AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate long-term durability and consistent outcomes at three years in a real-world setting.

The FDA lifted prescribing and dispensing restrictions on the drug rosiglitazone, saying it did not pose increased cardiac risks compared with other diabetes medications.

The FDA has given Boston Scientific the green light to market its next-generation durable polymer drug-eluting stent in the U.S.

AstraZeneca and Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Xigduo™ (dapagliflozin and metformin hydrochloride) for adults aged 18 and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their current metformin-based treatment regimen or who are currently being treated with the combination of dapgliflozin and metformin as separate tablets.

An intensive weight reduction and risk factor management program helped reduce atrial fibrillation (AF) symptoms more effectively than written and verbal weight reduction and exercise advice, according to a study published online Nov. 20 in JAMA.

The transition of transcatheter aortic valve replacement (TAVR) from a procedure performed at an initial 17 clinical trial sites with highly trained physicians to almost 250 facilities in the U.S. appears to be going smoothly, the registry leaders reported in the Nov. 20 issue of JAMA.

Evolocumab, a PCSK9 inhibitor, was safe and effective at lowering low-density lipoprotein cholesterol (LDL-C) after one year of treatment, according to a study published online Nov. 19 in Circulation and presented simultaneously at the American Heart Association scientific session in Dallas.

The first device of its kind to undergo clinical evaluation in the United States, the Valiant "Mona LSA" branch thoracic stent graft system from Medtronic, Inc. (NYSE: MDT) has demonstrated proof of concept in a first-in-human study being conducted under the U.S. Food and Drug Administration (FDA)'s "Innovation Pathway" early feasibility pilot program, according to data presented today at the 2013 VEITHsymposium(tm).